BioAlliance Pharma reinforces its development team with the appointment of Louis Kayitalire, MD, as Head of Research and Development

Paris, June 18, 2012 – BioAlliance Pharma SA (Euronext Paris - BIO), a Company dedicated to orphan oncology products and specialty products, today announces the reinforcement of its development team with the appointment of Louis Kayitalire, MD, as Head of Research and Development.

Directly reporting to the CEO, member of the Strategic Committee, Louis Kayitalire will be in charge of the development strategy of BioAlliance Pharma and of the development plan implementation, from preclinical phases to registration. Preclinical, clinical and regulatory teams will consequently report to him.

« I am delighted to welcome Louis. Thanks to his high expertise in cancer drug development, his knowledge of this area and his international experience, Louis will undoubtedly contribute to strengthen dynamics in building our position in the orphan oncology product domain. Moreover, he is joining the Company at a key stage of its strategic deployment in oncology, today with three products in an active development phase and determining milestones to come in the next months. I am sure that thanks to his large experience combined with his open and enthusiastic personality, he will rapidly and efficiently succeed in integrating the team", stated Judith Greciet, CEO of BioAlliance Pharma.

Medical oncologist from the Institut Gustave Roussy (Villejuif cancer research institute), Louis Kayitalire started his career at Eli Lilly in France and then in the United-States, before joining Bristol Myers Squibb Corporate (US) until 2007. He has collaborated to the development of several cancer drugs, from early phases to registration, of which some are today flagship cancer treatments.

Before joining BioAlliance Pharma, Louis Kayitalire was for 5 years Vice President Clinical Research for Oncology, Immunology/Inflammation and CNS/Pain at Cephalon Europe.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir®/Sitavig® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products

Livatag® (Doxorubicin Transdrug™) in primary liver cancer: Phase III on going

Validive® (Clonidine Lauriad™) in mucositis: Phase II on going

AMEP® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2011 Reference Document filed with the AMF on April 24, 2012, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com